1. India Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Eiko LifeSciences Ltd.

Eiko LifeSciences Ltd.

EIKO.BO
Eiko LifeSciences Ltd.IN flagBombay Stock Exchange
51.25
INR
+1.21
- -
735.23MMarket Cap

Total Valuation

Eiko LifeSciences Ltd. carries a market capitalization of 735.23M, placing it among publicly traded companies globally. Its enterprise value stands at 609.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap735.23M
Enterprise Value609.65M

Share Statistics

Eiko LifeSciences Ltd. currently has 14.49M shares outstanding.

Shares Outstanding14.49M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Eiko LifeSciences Ltd. trades at a trailing price-to-earnings ratio of 15.30. The price-to-sales ratio is 1.31, and the price-to-book ratio stands at 4.80.

PE Ratio15.30
PS Ratio1.31
PB Ratio4.80
P/TBV Ratio0.99
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Eiko LifeSciences Ltd. trades at an EV/EBITDA multiple of 9.49 and an EV/FCF ratio of 247.10. The EV/Sales ratio of 1.16 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.49 provides insight into valuation relative to core operating earnings.

EV / Sales1.16
EV / EBITDA9.49
EV / EBIT9.49
EV / FCF247.10

Financial Position

Eiko LifeSciences Ltd. maintains a current ratio of 3.08, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.77, indicating elevated leverage, while an interest coverage ratio of 19.47 demonstrates strong ability to service its debt obligations.

Current Ratio3.08
Quick Ratio0.89
Debt / Equity6.77
Debt / EBITDA0.74
Interest Coverage19.47

Financial Efficiency

Eiko LifeSciences Ltd. posts a return on equity of 26.75 and a return on invested capital of 7.12.

Return on Equity (ROE)26.75
Return on Assets (ROA)5.78
Return on Invested Capital (ROIC)7.12
Return on Capital Employed (ROCE)18.48
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover8.47

Taxes

Over the trailing twelve months, Eiko LifeSciences Ltd. has paid 17.93M in income taxes, reflecting an effective tax rate of 25.19.

Income Tax17.93M
Effective Tax Rate25.19

Stock Price Statistics

Eiko LifeSciences Ltd.'s stock has declined approximately -15.10684% over the past 52 weeks. The 50-day moving average sits at 50.67, while the 200-day moving average is 51.94.

Beta (5Y)N/A
52-Week Price Change-15.10684%
50-Day Moving Average50.67
200-Day Moving Average51.94
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Eiko LifeSciences Ltd. generated 527.07M in revenue and converted that into 44.96M in net income, yielding earnings per share of 3.77. EBITDA reached 64.21M, while operating income came in at 64.21M.

Revenue527.07M
Gross Profit114.11M
Operating Income64.21M
Pretax Income71.18M
Net Income44.96M
EBITDA64.21M
EBIT64.21M
Earnings Per Share (EPS)3.77

Balance Sheet

Eiko LifeSciences Ltd. holds 136.14M in cash and equivalents against 47.30M in total debt, resulting in a net debt position of -88.84M. Total book value stands at 143.46M, with working capital of 320.28M providing operational flexibility.

Cash & Cash Equivalents136.14M
Total Debt47.30M
Net Debt-88.84M
Equity (Book Value)143.46M
Book Value Per Share10.37
Working Capital320.28M

Margins

Eiko LifeSciences Ltd. operates with a gross margin of 21.65, reflecting its pricing power and cost economics. The operating margin of 12.18 and net profit margin of 8.53 provide insight into operational efficiency.

Gross Margin21.65
Operating Margin12.18
Pretax Margin13.50
Profit Margin8.53
EBITDA Margin12.18

Stock Splits

Eiko LifeSciences Ltd.'s most recent stock split took place on July 7, 2023 with a 1000:1153 split ratio.

Last Split Date7/7/2023
Split Ratio1000:1153

Scores

Eiko LifeSciences Ltd. posts an Altman Z-Score of 3.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.37